Jenewein Tina, Beckmann Britt-Maria, Scheiper-Welling Stefanie, Kauferstein Silke
Institut für Rechtsmedizin, Zentrum für plötzlichen Herztod und Kardiogenetik, Universitätsklinikum Frankfurt, Kennedyallee 104, 60590, Frankfurt, Deutschland.
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Standort RheinMain, Frankfurt, Deutschland.
Inn Med (Heidelb). 2025 Jul 11. doi: 10.1007/s00108-025-01934-0.
Sudden cardiac death (SCD) is an unexpected natural death with a suspected cardiac cause, accounting for approximately 20% of all cardiovascular deaths in Germany. A significant proportion of SCD in young people (< 50 years) are caused by hereditary arrhythmogenic diseases.
The European Society of Cardiology (ESC) guidelines recommend autopsy in all cases of unexpected sudden death, especially in young people, and post-mortem genetic testing (molecular autopsy) if a hereditary heart disease is suspected. Several studies show that molecular autopsy reveals a clinically relevant sequence variant associated with an inherited arrhythmogenic disease in about 20% of cases. Clinical cardiological and genetic testing of biologically related relatives of the deceased can reduce the risk of further deaths within affected families.
Based on molecular autopsy and clinical and genetic examination of relatives, therapeutic and preventive measures can be taken within families affected by SCD. This requires a structured approach to an SCD case by various medical disciplines within a financial and legal framework that has yet to be established in the German healthcare system.
心源性猝死(SCD)是一种由心脏原因导致的意外自然死亡,在德国约占所有心血管疾病死亡人数的20%。年轻人(<50岁)中相当一部分SCD是由遗传性心律失常疾病引起的。
欧洲心脏病学会(ESC)指南建议对所有意外猝死病例进行尸检,尤其是对年轻人,并且如果怀疑是遗传性心脏病,则进行死后基因检测(分子尸检)。多项研究表明,分子尸检在约20%的病例中发现了与遗传性心律失常疾病相关的具有临床意义的序列变异。对死者生物学上有亲属关系的亲属进行临床心脏病学和基因检测,可以降低受影响家庭中进一步死亡的风险。
基于分子尸检以及对亲属的临床和基因检查,可以在受SCD影响的家庭中采取治疗和预防措施。这需要德国医疗保健系统中尚未建立的财务和法律框架内,各医学学科对SCD病例采取结构化方法。